Healthcare Sales & Marketing Network News: interleukin-2

Searching News Database: interleukin-2

HSMN NewsFeed - 10 Feb 2025
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 7 Feb 2025
Most Patients on Lilly's Omvoh(R) (mirikizumab-mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing

HSMN NewsFeed - 7 Sep 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
Biopharmaceutical Gastroenterology Personnel

HSMN NewsFeed - 9 Aug 2021
SKYRIZI(R) (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Mar 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Jan 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Mar 2019
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 7 Jan 2019
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 16 May 2018
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 8 Jun 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 May 2017
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Dec 2016
Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis
Biopharmaceuticals Nerurology Regulatory

HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Sep 2012
EpiCept Regains Rights to Azixa(R) from Licensee Myrexis
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 3 Mar 2011
EpiCept Identifies Ceplene(R) Survival Benefit in Key AML Subgroup
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Dec 2010
EpiCept Announces Ceplene(R) Approved for Marketing in Israel
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Oct 2010
EpiCept Corporation and FDA Agree on Development Plan for Ceplene(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology

HSMN NewsFeed - 15 Jun 2010
Galera Therapeutics Secures Funding for New Cancer Treatment
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 May 2010
EpiCept Corporation Announces Commercial Launch of Ceplene(R) in Germany
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 19 Apr 2010
EpiCept Announces Commercial Launch of Ceplene(R) in the United Kingdom
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Mar 2010
FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 11 Jan 2010
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology

HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 12 Jun 2008
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Mar 2008
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing

HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals

HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2007
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 13 Nov 2007
AVAX Technologies announces the initiation of its Phase III Registration trial of M-Vax(R) in Metastatic Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 3 Oct 2007
Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 May 2007
Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2007
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Nov 2006
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Oct 2006
EpiCept Files for Marketing Approval of Ceplene(TM) in European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

Return to NewsFeed

Additional items found! 37

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 37 additional stories matching:
interleukin-2
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.